This is apparently an old issue but I was struck by this specific case. Myriad Genetics has a patent on the human BRCA gene and all of it's forms. This gene is linked to breast cancer and possibly other types of cancer, but since they have the patent, no research can be done by anyone other than Myriad without their blessing. (of money of course)
The ACLU has filed a lawsuit to stop this so I'm linking to their site because they have provided a lot of info on the subject.
American Civil Liberties Union : ACLU Challenges Patents On Breast Cancer Genes
The U.S. Patent and Trademark Office (PTO) has granted thousands of patents on human genes – in fact, about 20 percent of our genes are patented. A gene patent holder has the right to prevent anyone from studying, testing or even looking at a gene. As a result, scientific research and genetic testing has been delayed, limited or even shut down due to concerns about gene patents.The ACLU's take on the subject.As a result of the PTO granting patents on the BRCA genes to Myriad Genetics, Myriad's lab is the only place in the country where diagnostic testing can be performed. Because only Myriad can test for the BRCA gene mutations, others are prevented from testing these genes or developing alternative tests. Myriad's monopoly on the BRCA genes makes it impossible for women to access other tests or get a second opinion about their results, and allows Myriad to charge a high rate for their tests – over $3,000, which is too expensive for some women to afford.
"Knowledge about our own bodies and the ability to make decisions about our health care are some of our most personal and fundamental rights," said Anthony D. Romero, Executive Director of the ACLU. "The government should not be granting private entities control over something as personal and basic to who we are as our genes. Moreover, granting patents that limit scientific research, learning and the free flow of information violates the First Amendment."The patents granted to Myriad give the company the exclusive right to perform diagnostic tests on the BRCA1 and BRCA2 genes and to prevent any researcher from even looking at the genes without first getting permission from Myriad. According to the lawsuit, such monopolistic control over these genes hampers clinical diagnosis and serves as a disincentive for research because Myriad not only has the right to enforce its patents against other entities but also has the rights to future mutations discovered on the BRCA2 gene. The gene patents are also illegal under patent law because genes are "products of nature.""The patents on the BRCA genes block women's access to medical information necessary for making vital health care decisions, impeding their control over their own bodies," said Sandra Park, staff attorney with the ACLU Women's Rights Project.Here is the Myriad's response: In Gene Patent Case, Company Vows to Fight - The Lede Blog - NYTimes.com"Scientific research and testing have been delayed, limited or even shut down as a result of gene patents, stifling the development of new diagnostics and treatments," said Tania Simoncelli, ACLU science advisor. "The government should be encouraging scientific innovation, not hindering it."
Myriad understands that a lawsuit has been filed that challenges the legality and constitutionality of granting gene patents. However, Myriad has not yet been served in this matter. We intend to vigorously defend our intellectual property rights, if served in the lawsuit.It is our understanding that the core issue in the complaint revolves around the patenting of genes. Since a landmark U.S. Supreme Court decision in 1980 relating to gene patenting, the U.S. Patent and Trademark Office has granted tens of thousands of genetic and genetic-related patents, which cover a large number of life-saving pharmaceutical and diagnostic products. Myriad’s patent portfolio includes both “genetic” patents and patents on surrounding technologies required for testing.It sounds like a big FU to me.We have rights to 23 granted U.S. patents which cover a number of important aspects related to the detection of mutations in the BRCA1 and BRCA2 genes. These patents cover not only isolated gene sequences, but also methods of isolating, analyzing and detecting mutations. Myriad strongly believes its patents are valid and enforceable, and will be upheld by the courts.
Here is a link to the pdf of the siut for reference: http://www.aclu.org/images/asset_upl...e939_39568.pdf
XI Wiki


